Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prognostic impact of combined immunoprofiles in oropharyngeal squamous cell carcinoma patients with respect to AJCC 8th edition

D. Gurin, M. Slavik, M. Hermanova, T. Shatokhina, J. Sana, T. Kazda, I. Selingerova, P. Ahmad, P. Smilek, Z. Horakova, M. Hendrych, P. Slampa, O. Slaby,

. 2018 ; 47 (9) : 864-872. [pub] 20180825

Jazyk angličtina Země Dánsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012493

Grantová podpora
NV15-31627A MZ0 CEP - Centrální evidence projektů

OBJECTIVES: To examine combined immunoprofiles of epidermal growth factor receptor (EGFR), CD44, and p16 in oropharyngeal squamous cell carcinoma (OPSCC) and to correlate them with radiotherapy treatment outcomes and clinicopathological parameters. Prognostic impact of the American Joint Committee on Cancer (AJCC) 8th edition staging system in comparison with 7th edition was analyzed. METHODS: The study included 77 OPSCC patients treated by definitive intensity-modulated radiotherapy (IMRT). Clinical staging was assessed according to the AJCC, both 7th and 8th edition. Immunohistochemical (IHC) analysis of CD44 and EGFR was performed on primary biopsy tumor tissues. To evaluate the HPV status, IHC detection of p16 was employed. RESULTS: The AJCC 8th edition staging system revealed correlations between overall survival (OS), progression-free survival (PFS), locoregional control (LRC), and clinical stage. EGFR and CD44 positivity (+) and p16 negativity (-) were associated with clinical stage IV of the disease. CD44+ and EGFR+ OPSCC displayed worse OS and LRC, and these cases also showed the worst 3-year OS and LRC. Combined analysis of protein expressions identified an association between p16- and EGFR+, p16- and CD44+, EGFR+, and CD44+. Combined immunoprofiles CD44+/p16-, EGFR+/p16-, and EGFR+/CD44+ were associated with worst OS and LRC. CONCLUSIONS: Combined immunoprofiles of p16, EGFR, and CD44 might provide valuable prognostic and predictive information for the individual OPSCC patients, especially in terms of response to IMRT and prediction of treatment outcomes. Application of the AJCC 8th edition staging for HPV+ OPSCC proved to improve hazard discrimination and prognostication of OPSCC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012493
003      
CZ-PrNML
005      
20201105101010.0
007      
ta
008      
190405s2018 dk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jop.12772 $2 doi
035    __
$a (PubMed)30079604
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a dk
100    1_
$a Gurin, Dominik $u 1st Department of Pathology, St. Anne's University Hospital and Medical Faculty, Masaryk University, Brno, Czech Republic.
245    10
$a Prognostic impact of combined immunoprofiles in oropharyngeal squamous cell carcinoma patients with respect to AJCC 8th edition / $c D. Gurin, M. Slavik, M. Hermanova, T. Shatokhina, J. Sana, T. Kazda, I. Selingerova, P. Ahmad, P. Smilek, Z. Horakova, M. Hendrych, P. Slampa, O. Slaby,
520    9_
$a OBJECTIVES: To examine combined immunoprofiles of epidermal growth factor receptor (EGFR), CD44, and p16 in oropharyngeal squamous cell carcinoma (OPSCC) and to correlate them with radiotherapy treatment outcomes and clinicopathological parameters. Prognostic impact of the American Joint Committee on Cancer (AJCC) 8th edition staging system in comparison with 7th edition was analyzed. METHODS: The study included 77 OPSCC patients treated by definitive intensity-modulated radiotherapy (IMRT). Clinical staging was assessed according to the AJCC, both 7th and 8th edition. Immunohistochemical (IHC) analysis of CD44 and EGFR was performed on primary biopsy tumor tissues. To evaluate the HPV status, IHC detection of p16 was employed. RESULTS: The AJCC 8th edition staging system revealed correlations between overall survival (OS), progression-free survival (PFS), locoregional control (LRC), and clinical stage. EGFR and CD44 positivity (+) and p16 negativity (-) were associated with clinical stage IV of the disease. CD44+ and EGFR+ OPSCC displayed worse OS and LRC, and these cases also showed the worst 3-year OS and LRC. Combined analysis of protein expressions identified an association between p16- and EGFR+, p16- and CD44+, EGFR+, and CD44+. Combined immunoprofiles CD44+/p16-, EGFR+/p16-, and EGFR+/CD44+ were associated with worst OS and LRC. CONCLUSIONS: Combined immunoprofiles of p16, EGFR, and CD44 might provide valuable prognostic and predictive information for the individual OPSCC patients, especially in terms of response to IMRT and prediction of treatment outcomes. Application of the AJCC 8th edition staging for HPV+ OPSCC proved to improve hazard discrimination and prognostication of OPSCC.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x analýza $7 D014408
650    _2
$a spinocelulární karcinom $x diagnóza $x patologie $7 D002294
650    _2
$a inhibitor p16 cyklin-dependentní kinasy $x analýza $7 D019941
650    _2
$a erbB receptory $x analýza $7 D066246
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a antigeny CD44 $x analýza $7 D018960
650    12
$a imunohistochemie $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $x metody $7 D009367
650    _2
$a nádory orofaryngu $x diagnóza $x patologie $7 D009959
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
700    1_
$a Slavik, Marek $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute and Medical Faculty, Masaryk University, Brno, Czech Republic.
700    1_
$a Hermanova, Marketa $u 1st Department of Pathology, St. Anne's University Hospital and Medical Faculty, Masaryk University, Brno, Czech Republic.
700    1_
$a Shatokhina, Tetiana $u 1st Department of Pathology, St. Anne's University Hospital and Medical Faculty, Masaryk University, Brno, Czech Republic.
700    1_
$a Sana, Jiri $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Kazda, Tomas $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute and Medical Faculty, Masaryk University, Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Selingerova, Iveta $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Department of Mathematics and Statistics, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Ahmad, Parwez $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Smilek, Pavel $u Department of Otorhinolaryngology and Head and Neck Surgery, St. Anne's University Hospital and Medical Faculty, Masaryk University, Brno, Czech Republic.
700    1_
$a Horakova, Zuzana $u Department of Otorhinolaryngology and Head and Neck Surgery, St. Anne's University Hospital and Medical Faculty, Masaryk University, Brno, Czech Republic.
700    1_
$a Hendrych, Michal $u 1st Department of Pathology, St. Anne's University Hospital and Medical Faculty, Masaryk University, Brno, Czech Republic. Department of Physiology, Medical Faculty, Masaryk University, Brno, Czech Republic.
700    1_
$a Slampa, Pavel $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute and Medical Faculty, Masaryk University, Brno, Czech Republic.
700    1_
$a Slaby, Ondrej $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
773    0_
$w MED00007685 $t Journal of oral pathology & medicine official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology $x 1600-0714 $g Roč. 47, č. 9 (2018), s. 864-872
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30079604 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20201105101007 $b ABA008
999    __
$a ok $b bmc $g 1391803 $s 1050798
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 47 $c 9 $d 864-872 $e 20180825 $i 1600-0714 $m Journal of oral pathology & medicine $n J Oral Pathol Med $x MED00007685
GRA    __
$a NV15-31627A $p MZ0
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace